| Literature DB >> 31272480 |
Natalia Molinero1, Lorena Ruiz1,2, Christian Milani3, Isabel Gutiérrez-Díaz4, Borja Sánchez1, Marta Mangifesta3, José Segura2, Isabel Cambero2, Ana Belén Campelo1, Carmen María García-Bernardo5, Ana Cabrera6, José Ignacio Rodríguez6, Sonia González4, Juan Miguel Rodríguez2, Marco Ventura3,7, Susana Delgado8, Abelardo Margolles9.
Abstract
BACKGROUND: The microbial populations of the human intestinal tract and their relationship to specific diseases have been extensively studied during the last decade. However, the characterization of the human bile microbiota as a whole has been hampered by difficulties in accessing biological samples and the lack of adequate methodologies to assess molecular studies. Although a few reports have described the biliary microbiota in some hepatobiliary diseases, the bile microbiota of healthy individuals has not been described. With this in mind, the goal of the present study was to generate fundamental knowledge on the composition and activity of the human bile microbiota, as well as establishing its potential relationship with human bile-related disorders.Entities:
Keywords: Bile microbiota; Cholelithiasis; Gallstones patients; Microbial bile metabolites
Year: 2019 PMID: 31272480 PMCID: PMC6610825 DOI: 10.1186/s40168-019-0712-8
Source DB: PubMed Journal: Microbiome ISSN: 2049-2618 Impact factor: 14.650
Demographic and clinical features of cholelithiasis patients
| Subject | Age (years) | Sex | Clinical history | Altered parameters in blood test (with higher levels than those considered normal)a |
|---|---|---|---|---|
| C-01 | 73 | F | Non-cirrhotic portal hypertension. Alteration of liver function due to chemotherapy. Digestive hemorrhage (2 years before collecting the bile sample) | ALP, AST, and GGT |
| C-02 | 67 | M | Hemicolectomy (3 years before collecting the bile sample) | GGT, TB, DB, and TG |
| C-03 | 60 | F | Hypercholesterolemia | – |
| C-04 | 58 | F | – | AST and GGT |
| C-05 | 67 | M | – | DB and TB |
| C-06 | 55 | F | Obesity type II (BMI 38.5) | ALT, AST, Glu, GGT, and TC |
| C-07 | 27 | F | – | – |
| C-08 | 50 | M | Obesity type I (BMI 32.2) Acute lithiasic pancreatitis (7 months before collecting the bile sample) | GGT, LDL, TC, and TG |
| C-09 | 38 | F | – | LDL and TC |
| C-10 | 33 | F | – | – |
| C-11 | 36 | F | Obesity type II (BMI 36.1) | ALT and GGT |
| C-12 | 44 | F | – | TG |
| C-13 | 50 | F | – | ALT and AST |
| C-14 | 70 | F | – | DB, GGT, and TB |
– no relevant information, BMI body mass index, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, DB direct bilirubin, GGT gamma-glutamyl transferase, Glu glucose, LDL cholesterol LDL, TB total bilirubin, TC total cholesterol, TG triglycerides, F female, M male
aAt the time of sampling
Fig. 1Boxplots representing 16S rRNA gene and 18S rRNA gene levels in the control group (n = 13). The central rectangles represent interquartile ranges (IQR), the lines inside the rectangles show the median, and the whiskers indicate the maximum and minimum values. The dots outside the rectangles are suspected outliers (> 1.5 × IQR). Statistically significant differences (p value < 0.05) between the two variables (16S rRNA gene and 18S rRNA gene) were found (Mann-Whitney U test)
Percentages (%) of quality and human filtered reads assigned at the ranks of superkingdom and phylum from three control bile samples subjected to shotgun metagenomics
| Taxonomic assignment | Sample code | |||
|---|---|---|---|---|
| Superkingdom | Phyluma | H-04 | H-05 | H-06 |
| Not assigned | 32.67 | 20.96 | 33.13 | |
| Archaea | 0.02 | 0.06 | 0.04 | |
| Eukaryota | 2.11 | 0.21 | 1.83 | |
| Viruses | 0.12 | 5.58 | 0.20 | |
| Bacteria | 65.08 | 73.19 | 64.79 | |
|
| 13.17 | 2.91 | 12.23 | |
|
| 34.36 | 34.22 | 35.60 | |
|
| 22.47 | 56.51 | 23.10 | |
|
| 27.80 | 5.46 | 27.06 | |
|
| 0.16 | 0.43 | 0.25 | |
|
| 0.73 | 0.01 | 0.55 | |
|
| 0.18 | 0.04 | 0.14 | |
|
| 0.20 | 0.05 | 0.20 | |
|
| 0.14 | 0.07 | 0.12 | |
|
| 0.09 | 0.05 | 0.10 | |
|
| 0.05 | 0.08 | 0.09 | |
|
| 0.02 | 0.00 | 0.01 | |
|
| 0.00 | 0.00 | 0.02 | |
|
| 0.00 | 0.02 | 0.00 | |
|
| 0.11 | 0.03 | 0.08 | |
|
| 0.03 | 0.01 | 0.03 | |
|
| 0.00 | 0.00 | 0.02 | |
|
| 0.00 | 0.00 | 0.01 | |
| Unclassified bacteria | 0.49 | 0.21 | 0.38 | |
aAbundances of different phyla are related to total assigned bacteria sequences
Fig. 2Distribution of Clusters of Orthologous Groups (COGs) in three bile samples from control group (H-04, H-05, and H-06). The results show the percentage of sequences assigned to different metabolic functions (relative to all sequenced microbes). Secondary metabolite biosynthesis includes antibiotics, pigments, and non-ribosomal peptides. Inorganic ion transport and metabolism includes phosphate, sulfate, and various cation transporters
Microbial functional genes related to the metabolism of cholesterol and BA assigned (ratio 1/10,000 reads) through MetaCyc metabolic pathway database in three metagenomes from human bile and five fecal metagenomes from healthy subjects from a previous study [20]
| Bile samples | Fecal samples | Average bile | Average gut | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pathway | H-04 | H-05 | H-06 | 2HS | 26HS | 30HS | 31HS | 32HS | ||
| Cholesterol biosynthesis I | 0.13 | 0.02 | 0.29 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.15 ± 0.11 | 0.02 ± 0.03 |
| Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | 0.13 | 0.02 | 0.29 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.15 ± 0.11 | 0.02 ± 0.03 |
| Cholesterol biosynthesis III (via desmosterol) | 0.13 | 0.02 | 0.29 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.15 ± 0.11 | 0.02 ± 0.03 |
| Superpathway of cholesterol biosynthesis | 0.37 | 3.29 | 15.31 | 0.12 | 0.21 | 0.25 | 1.06 | 0.25 | 6.32 ± 6.47 | 0.38 ± 0.34 |
| Superpathway of cholesterol degradation I (cholesterol oxidase) | 1.06 | 0.17 | 0.21 | 0.41 | 0.46 | 0.39 | 0.48 | 0.71 | 0.48 ± 0.41 | 0.49 ± 0.11 |
| Superpathway of cholesterol degradation II (cholesterol dehydrogenase) | 1.52 | 0.34 | 0.36 | 0.54 | 0.5 | 0.47 | 0.62 | 0.81 | 0.74 ± 0.55 | 0.59 ± 0.12 |
| Cholesterol degradation to androstenedione I (cholesterol oxidase) | 0.35 | 0.02 | 0.07 | 0.00 | 0 | 0.00 | 0.01 | 0.02 | 0.15 ± 0.15 | 0.01 ± 0.01 |
| Cholesterol degradation to androstenedione II (cholesterol dehydrogenase) | 0.74 | 0.05 | 0.21 | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 | 0.33 ± 0.29 | 0.02 ± 0.02 |
| Bile acid biosynthesis, neutral pathway | 0.61 | 0.07 | 0.29 | 0.06 | 0.06 | 0.02 | 0.11 | 0.05 | 0.32 ± 0.22 | 0.06 ± 0.03 |
| Glycocholate metabolism (bacteria) | 1.58 | 2.71 | 0.72 | 10.58 | 15.03 | 12.4 | 15.53 | 12.35 | 1.67 ± 0.81 | 13.18 ± 1.84 |
| Cholate degradation (bacteria, anaerobic) | 0.35 | 0.46 | 0.14 | 0.97 | 0.77 | 0.41 | 0.62 | 0.38 | 0.32 ± 0.13 | 0.63 ± 0.22 |
Fig. 3Boxplots representing 16S rRNA gene levels between cholelithiasis (n = 14) and control group (n = 13). The central rectangles represent interquartile ranges (IQR), the lines inside the rectangles show the median, and the whiskers indicate the maximum and minimum values. The dots outside the rectangles are suspected outliers (> 1.5 × IQR). Statistically significant differences (p value < 0.05) between the two groups of the study were not found (Mann-Whitney U test)
Differences in microbial relative abundance (% of sequences) in bile at family level between cholelithiasis patients and the control group. Only families with a mean relative abundance higher than 0.5% are presented. Only families that were detected in more than half of the samples in each group were considered for the analysis
Differences in microbial relative abundance (% of sequences) in bile at genus level between cholelithiasis patients and the control group. Only genera with a mean relative abundance higher than 0.5% are presented. Only genera that were detected in more than half of the samples in each group were considered for the analysis
Fig. 4Comparison of Shannon’s diversity indices in cholelithiasis (n = 14) and control (n = 13) groups. The central rectangles represent interquartile ranges (IQR), the lines inside the rectangles show the median, and the whiskers indicate the maximum and minimum values. The dots outside the rectangles are suspected outliers (> 1.5 × IQR). Statistically significant differences (p value < 0.05) between groups were found (Mann-Whitney U test)
Fig. 5Principal Coordinate Analysis (PCoA) plot of weighted UniFrac distances, comparing the bacterial communities among samples from cholelithiasis (red circles, n = 14) and control group (blue circles, n = 13). Percentages shown in the axes represent the proportion of dissimilarities. Analysis of molecular variance (AMOVA) was used to assess the statistical significance of the spatial separation between both groups (p value < 0.001)
Signal assignments for 1H-NMR spectra obtained from gallbladder bile
| Chemical shift | Compounds |
|---|---|
| 0.00 | TSP (internal standard) |
| 0.67 | BA (H18) |
| 0.71 | Cholesterol (H18) |
| 1.42 | Lipids (CH2)n |
| 1.49 | BA cholesterol + lipids |
| 2.38 | BA cholesterol + lipids |
| 2.74 | Lipids |
| 2.78 | Lipids |
| 2.81 | Lipids |
| 3.07 | Conjugated taurine |
| 3.24 | Phosphatidylcholine |
| 3.49 | CA+CDCA |
| 3.56 | DCA + conjugated taurine |
| 3.63 | Phosphatidylcholine |
| 3.74 | Conjugated glycine |
| 3.84 | CA+DCA |
| 3.88 | CA, CDA, + PC-glycerol |
| 4.28 | PC-glycerol |
| 4.31 | Phosphatidylcholine |
| 4.44 | PC-glycerol |
| 4.46 | PC-glycerol |
| 4.83 | Residual water |
| 5.32 | Lipids, cholesterol PC-glycerol |
| 7.83 | Glycochenodeoxycholic acid |
| 7.86 | Glycodeoxycholic acid |
| 7.88 | Glycocholic acid |
| 7.99 | Taurochenodeoxycholic acid |
| 8.00 | Taurodeoxycholic acid |
| 8.01 | Taurocholic acid |
BA bile acids, CA cholic acid (primary), CDCA chenodeoxycholic acid (primary), DCA deoxycholic acid (secondary), TSP 3-(trimethylsilyl) propionicacid-d4, PC-glycerol phosphatidylcholine-glycerol
Fig. 6Principal component analysis (PCA) plot of bile metabolites. PC1 versus PC2 obtained for the whole spectra is represented. Control samples are represented in black. Blue dots belong to bile samples from cholelithiasis patients